Ernexa Therapeutics Inc（ERNA）财务数据ERNAErnexa Therapeutics Inc

Ernexa Therapeutics Inc (ERNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Subscription revenue, accounting for 93.9% of total sales, equivalent to $1.10M. Other significant revenue streams include Other revenue and Hardware revenue. Understanding this composition is critical for investors evaluating how ERNA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ernexa Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -321.22%, provide a clear picture of how effectively ERNA converts its operational activities into shareholder value.

In the context of the broader market, ERNA competes directly with industry leaders such as BOLT and ACXP. With a market capitalization of $6.97M, it holds a significant position in the sector. When comparing efficiency, ERNA's gross margin of N/A stands against BOLT's 100.00% and ACXP's N/A. Such benchmarking helps identify whether Ernexa Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Eterna Therapeutics has shown a gross margin of 112.32% in Q3 2024, which is exceptionally high, although it has not generated significant revenue in subsequent quarters. The company reported a net income loss of $5.51 million in Q1 2026, an improvement from previous losses, indicating a trend towards better financial performance.